Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 8/20 | 0.80 |
| ▸ | CYP26A1 | O43174 | 8/20 | 0.80 |
| ▸ | RARB | P10826 | 7/20 | 0.80 |
| ▸ | RARG | P13631 | 7/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 2/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | TSHR | P16473 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
| ▸ | CYP26B1 | Q9NR63 | 5/20 | 0.70 |
| ▸ | PGR | P06401 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.67 |
| ▸ | BLVRB | P30043 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19560600 | 0.91 | RARA (0.80) | RARACYP26A1RARBRARGCYP3A4 | |
| SCHEMBL9446527 | 0.89 | CYP26A1 (0.80) | RARACYP26A1RARBRARGCYP3A4 | |
| SCHEMBL726740 | 0.89 | RARB (1.00) | RARACYP26A1RARBRARGCYP3A4 | |
| SCHEMBL29355626 | 0.89 | RARB (1.00) | RARACYP26A1RARBRARGCYP3A4 | |
| SCHEMBL1616078 | 0.87 | CYP26A1 (0.78) | RARACYP26A1RARBRARGCYP3A4 | |
| SCHEMBL1616121 | 0.87 | CYP26A1 (0.78) | RARACYP26A1RARBRARGCYP3A4 | |
| SCHEMBL9446600 | 0.87 | RARA (0.78) | RARACYP26A1RARBRARGCYP3A4 | |
| SCHEMBL7621355 | 0.87 | RARA (0.82) | RARACYP26A1RARBRARGCYP3A4 | |
| SCHEMBL8461267 | 0.86 | RARA (0.76) | RARACYP26A1RARBRARGCYP3A4 | |
| SCHEMBL1615390 | 0.86 | RARA (0.76) | RARACYP26A1RARBRARGCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221392-B2 | Generation of pancreatic endoderm from pluripotent stem cells using small molecules | NOVO NORDISK A/S (DK) | 2019-03-05 | — | — | US | disclosed |
| US-20150246075-A1 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT | CHILDREN'S MEDICAL CENTER CORPORATION | 2015-09-03 | — | — | US | disclosed |
| US-9056085-B2 | Methods for enhancing hematopoietic stem/progenitor cell engraftment | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2015-06-16 | — | — | US | disclosed |
| US-5869067-A | TREATING DERMATOLOGICAL DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1999-02-09 | — | — | US | disclosed |
| US-5753239-A | Bi-aromatic compounds and pharmaceutical and cosmetic compositions | CENTRE INTERNATIONAL DE RECHERCHES DEMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1998-05-19 | — | — | US | disclosed |
| EP-0514269-B1 | Imino-derivatives, process for their preparation and their use in human and veterinary medicine and in cosmetics | CIRD GALDERMA (FR) | 1995-11-02 | — | — | EP | disclosed |
| EP-0514269-A1 | Imino-derivatives, process for their preparation and their use in human and veterinary medicine and in cosmetics | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246075-A1 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT | HCLS1, MCL1, THPO | RARA 183/4885CYP26A1 2754/4885RARB 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.